Compare TRN & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRN | IMNM |
|---|---|---|
| Founded | 1933 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Railroads | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.6B |
| IPO Year | 1994 | 2020 |
| Metric | TRN | IMNM |
|---|---|---|
| Price | $34.09 | $18.17 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $34.00 | $32.80 |
| AVG Volume (30 Days) | 703.7K | ★ 1.1M |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | ★ 4.03% | N/A |
| EPS Growth | ★ 85.98 | 51.40 |
| EPS | ★ 0.30 | N/A |
| Revenue | ★ $2,156,900,000.00 | $6,941,000.00 |
| Revenue This Year | $1.91 | N/A |
| Revenue Next Year | $15.61 | $1,127.34 |
| P/E Ratio | $113.83 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $22.38 | $7.96 |
| 52 Week High | $37.36 | $27.65 |
| Indicator | TRN | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 55.62 | 32.49 |
| Support Level | $31.12 | $16.81 |
| Resistance Level | $35.33 | $19.16 |
| Average True Range (ATR) | 1.02 | 1.16 |
| MACD | 0.12 | -0.33 |
| Stochastic Oscillator | 82.73 | 0.00 |
Trinity Industries Inc sells and leases railroad products and railcar maintenance services in North America. The company operates under the name TrinityRail in two main segments: railcar leasing and management services, which owns railcars and provides fleet management and administration services; rail products, which builds, sells, and modifies freight and tank railcars and their components; and all other, which sells highway products such as guardrail and other highway barriers. Customers include railroads, leasing companies, and shipping companies in agriculture, construction, consumer products, energy, and chemicals.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.